Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Ian Green

CEO, Terrence Higgins Trust

Recent stories

  • Unanswered questions about proposed PrEP trial Subscription

    7 DEC 2016

    With 17 new HIV diagnoses made every day in the UK, we need to be bold and ambitious in our approach to HIV prevention — and this must include access to pre-exposure prophylaxis (PrEP) for all who need it. For two years we have been calling for a long-term, stable home for PrEP within the NHS so it can be used as a vital tool in our HIV prevention armoury alongside condoms, regular testing and early treatment. We welcome the fact that, finally, PrEP will be made available to 10,

  • NHS England pulling the plug on PrEP for HIV prevention is unacceptableSubscription

    23 MAR 2016

    I wish to draw your attention to NHS England’s sudden abandonment of its own processes in a shocking U-turn on access to HIV game changer pre-exposure prophylaxis (PrEP; emtricitabine/tenofovir, marketed as Truvada). The HIV sector has been waiting for the announcement of the first ever public consultation on PrEP since the end of January 2016. This was one of the final steps before a decision would have been made on NHS availability for PrEP — already available in the United States, F

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.